{ "model": { "rank": 5135, "code": "thing-q26272", "model_id": "vr.tr.atropine", "name": "atropine", "purpose": "Enable an agent to identify atropine, assess evidence about its material state and biological activity, and determine which handling or use decisions require product-specific authority.", "family": "Thing Registry", "category": "Physical world and living systems", "status": "research-draft", "kind": "thing", "plane": "PHY", "domain": "PHY.OBJ", "industry": "", "version": "", "url": "/models/thing/q26272/", "tier": 2, "score": 69, "payload": { "layer": "wikidata", "aliases": [], "aliasCount": 0, "merged": 0, "knownIn": 69, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": "vr.tr.atropine", "source": { "dataset": "wikidata", "item": "Q26272", "url": "https://www.wikidata.org/wiki/Q26272", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-09T21:44:34Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 21.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a08820-3373-7a13-ac4c-9cbc4d648844\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: atropine\nSense to describe: (none recorded)\nDomain code: PHY.OBJ\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 005: 1001 regist", "usd": 0, "recall": true }, "codex": { "seconds": 67.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a08820-3362-7bd0-b7f2-55f33a05f8c6\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: atropine\nRegistry id: vr.tr.atropine\nPlane / domain: PHY / PHY.OBJ\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nContex" } } }, "metaModel": { "id": "THING-Q26272", "registryId": "vr.tr.atropine", "name": "atropine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.OBJ" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q26272/", "model": { "registry_id": "vr.tr.atropine", "name": "atropine", "purpose": "Enable an agent to identify atropine, assess evidence about its material state and biological activity, and determine which handling or use decisions require product-specific authority.", "definition": "Atropine is a tropane alkaloid consisting of a racemic mixture of hyoscyamine enantiomers that competitively antagonizes muscarinic acetylcholine receptors.", "scope_statement": "This model owns atropine as the racemic chemical substance registered as vr.tr.atropine in PHY / PHY.OBJ, including distinctions between its molecular identity, salt forms, measured samples and participation in medicinal products.", "in_scope": [ "Chemical identity and racemic stereochemical composition", "Free-base, salt and hydration-state distinctions", "Atropine content, analytical identity, impurities and degradation", "Muscarinic antagonism and boundaries of biological effects", "Substance-specific handling and links to formulation-specific requirements" ], "out_of_scope": [ "Hyoscyamine and scopolamine as independently modelled substances", "Atropine-producing plants and botanical extracts as whole organisms or mixtures", "Finished medicinal products, packaging and delivery devices", "Patient diagnosis, prescribing and dosing protocols", "Poisoning events and complete emergency treatment pathways" ], "distinguishing_features": [ "Require evidence of racemic hyoscyamine composition to distinguish atropine from an isolated hyoscyamine enantiomer; a shared molecular formula is insufficient. Reference: [PubChem atropine](https://pubchem.ncbi.nlm.nih.gov/compound/Atropine).", "Check counterion and hydration information before treating atropine free base and atropine sulfate monohydrate as the same weighed material.", "Use structure-sensitive identification to distinguish atropine from related tropane alkaloids such as scopolamine; plant origin or antimuscarinic activity alone cannot identify it.", "Distinguish an atropine-containing formulation or botanical mixture from the substance itself by recording other constituents and the analytical basis for atropine identification." ], "characteristics": [ { "name": "Stereochemical composition", "kind": "measurement", "unit_or_values": "Enantiomer fractions or ratio, with method and uncertainty", "why_it_matters": "Tests the racemic identity and prevents conflation with isolated hyoscyamine." }, { "name": "Chemical form", "kind": "category", "unit_or_values": "Free base; named salt with stoichiometry; specified hydrate; unresolved", "why_it_matters": "Determines what a mass, identifier or material specification actually describes." }, { "name": "Atropine assay", "kind": "measurement", "unit_or_values": "% mass fraction or mg/mL, explicitly stating free-base or salt basis", "why_it_matters": "Makes content comparisons interpretable across solids and formulations." }, { "name": "Related-substance profile", "kind": "measurement", "unit_or_values": "Named impurity concentrations in %, mg/g or another declared unit, with detection limits", "why_it_matters": "Separates atropine content from accompanying alkaloids and degradation products." }, { "name": "Material condition", "kind": "state", "unit_or_values": "Conforms to stated specification; degraded; contaminated; unassessed", "why_it_matters": "Supports a decision about whether the material remains suitable for its declared purpose." }, { "name": "Biological target", "kind": "relation", "unit_or_values": "Muscarinic receptor target linked to assay, endpoint and biological system", "why_it_matters": "Connects identity to measured activity without turning an assay result into a treatment claim." }, { "name": "Formulation participation", "kind": "relation", "unit_or_values": "Ingredient of a specified product, with strength basis and labelled route", "why_it_matters": "Keeps medicinal-product permissions attached to the product that establishes them." }, { "name": "Storage and exposure history", "kind": "state", "unit_or_values": "Recorded temperature, light, moisture and opening history compared with applicable requirements", "why_it_matters": "Supports review of stability evidence and potential excursions." } ], "affordances": [ "Match an asserted atropine identity against chemical-form and stereochemical evidence.", "Compare atropine content across materials after verifying salt, hydrate and reporting basis.", "Flag unresolved identity, impurity or stability evidence for analytical review.", "Connect a material to the applicable specification, safety information and product label.", "Distinguish evidence of muscarinic antagonism from evidence supporting a particular clinical use." ] }, "sources": [], "structure": { "bundles": [ { "id": "chemical-identity", "name": "Chemical identity", "description": "Establish what the name atropine denotes and which material forms instantiate it.", "rationale": "A name match can conceal differences in stereochemistry, counterion and hydration.", "layers": [ { "id": "racemic-identity", "name": "Racemic identity", "description": "Separate atropine from individual hyoscyamine enantiomers and related alkaloids.", "findings": [ { "id": "stereochemistry-defines-atropine", "name": "Stereochemistry defines atropine", "description": "Atropine denotes racemic hyoscyamine; identity evidence must preserve that distinction. Reference: [PubChem atropine](https://pubchem.ncbi.nlm.nih.gov/compound/Atropine).", "questions": [ { "text": "Does the cited chemical record explicitly represent the racemate?", "kind": "definition", "id": "stereochemistry-defines-atropine-q01" }, { "text": "What enantiomer-resolving evidence supports identification of this sample as atropine?", "kind": "measurement", "id": "stereochemistry-defines-atropine-q02" } ] } ] }, { "id": "base-salts-and-hydrates", "name": "Base, salts and hydrates", "description": "Track chemical form without creating a duplicate model for each product presentation.", "findings": [ { "id": "form-specific-identity", "name": "Form-specific identity", "description": "Represent counterion, stoichiometry and hydration explicitly wherever a record describes a salt rather than atropine free base.", "questions": [ { "text": "Does the identifier refer to atropine free base, a salt or a particular hydrate?", "kind": "boundary", "id": "form-specific-identity-q01" }, { "text": "Which certificate or analytical record establishes counterion and water content?", "kind": "provenance", "id": "form-specific-identity-q02" } ] } ] } ] }, { "id": "origin-and-analytical-confirmation", "name": "Origin and analytical confirmation", "description": "Separate reported origin from demonstrated atropine identity and composition.", "rationale": "Botanical association and nonspecific alkaloid measurements cannot establish a pure racemic substance.", "layers": [ { "id": "origin-and-stereochemical-history", "name": "Origin and stereochemical history", "description": "Record sourcing and processing evidence relevant to the observed enantiomer composition.", "findings": [ { "id": "origin-does-not-establish-racemate", "name": "Origin does not establish racemate", "description": "Keep plant association, extraction history and confirmed racemic composition as separate assertions.", "questions": [ { "text": "Was the material obtained through botanical extraction, synthesis or an undocumented route?", "kind": "provenance", "id": "origin-does-not-establish-racemate-q01" }, { "text": "What evidence distinguishes its initial stereochemical composition from changes during processing or analysis?", "kind": "provenance", "id": "origin-does-not-establish-racemate-q02" } ] } ] }, { "id": "selective-identification", "name": "Selective identification", "description": "Assess whether analytical methods distinguish atropine from neighbouring chemical identities.", "findings": [ { "id": "method-selectivity", "name": "Method selectivity", "description": "Record whether an assay resolves related tropane alkaloids and enantiomers rather than reporting an undifferentiated signal.", "questions": [ { "text": "Which reference standard and analytical method support the atropine assignment?", "kind": "provenance", "id": "method-selectivity-q01" }, { "text": "Can the method distinguish atropine from scopolamine, isolated hyoscyamine and relevant impurities?", "kind": "measurement", "id": "method-selectivity-q02" } ] } ] } ] }, { "id": "content-and-material-integrity", "name": "Content and material integrity", "description": "Make atropine quantity and fitness interpretable across chemical forms and sample conditions.", "rationale": "An unqualified strength or purity value can misrepresent both available atropine and material quality.", "layers": [ { "id": "assay-reporting-basis", "name": "Assay reporting basis", "description": "Attach every content value to the chemical entity and preparation basis being measured.", "findings": [ { "id": "content-needs-a-basis", "name": "Content needs a basis", "description": "Specify whether content is expressed as atropine free base or a named salt, and whether solid-material results use an as-received or corrected basis.", "questions": [ { "text": "What entity, unit and moisture correction does the reported assay use?", "kind": "measurement", "id": "content-needs-a-basis-q01" }, { "text": "Are salt stoichiometry, hydration and concentration conventions sufficiently established to compare these quantities?", "kind": "action", "id": "content-needs-a-basis-q02" } ] } ] }, { "id": "impurities-and-stability", "name": "Impurities and stability", "description": "Relate compositional changes to the specification and stability evidence for the actual material.", "findings": [ { "id": "integrity-requires-specific-evidence", "name": "Integrity requires specific evidence", "description": "Assess related alkaloids and degradation products using applicable methods and limits; appearance alone does not establish atropine integrity.", "questions": [ { "text": "Which impurities and degradation products does the applicable specification require the assay to resolve?", "kind": "measurement", "id": "integrity-requires-specific-evidence-q01" }, { "text": "What stability evidence supports acceptance after the recorded storage conditions or excursions?", "kind": "action", "id": "integrity-requires-specific-evidence-q02" } ] } ] } ] }, { "id": "muscarinic-activity-and-boundaries", "name": "Muscarinic activity and boundaries", "description": "Represent atropine's pharmacological action with explicit limits on interpretation.", "rationale": "A receptor mechanism does not establish every claimed physiological outcome or treatment capability.", "layers": [ { "id": "receptor-action", "name": "Receptor action", "description": "Connect atropine to target-specific evidence.", "findings": [ { "id": "muscarinic-antagonism", "name": "Muscarinic antagonism", "description": "Atropine is a competitive, reversible muscarinic receptor antagonist. Reference: [PubChem atropine](https://pubchem.ncbi.nlm.nih.gov/compound/Atropine).", "questions": [ { "text": "Which receptor subtype, biological system and endpoint does the activity evidence address?", "kind": "measurement", "id": "muscarinic-antagonism-q01" }, { "text": "Was activity measured for racemic atropine, an isolated enantiomer or a formulation?", "kind": "boundary", "id": "muscarinic-antagonism-q02" } ] } ] }, { "id": "effect-and-treatment-limits", "name": "Effect and treatment limits", "description": "Separate receptor blockade from broader claims about poisoning reversal and clinical benefit.", "findings": [ { "id": "antidote-claim-has-limits", "name": "Antidote claim has limits", "description": "A cited injection label specifies blockade of severe muscarinic effects, including in certain poisonings; preserve that boundary when recording antidotal use. Reference: [DailyMed atropine sulfate label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=423fc064-57cb-8308-e063-6394a90a2617&version=1).", "questions": [ { "text": "Which claimed effect is supported by muscarinic blockade, and which requires separate mechanistic evidence?", "kind": "boundary", "id": "antidote-claim-has-limits-q01" }, { "text": "Does a poisoning-use statement distinguish symptom control from enzyme reactivation and other treatment requirements?", "kind": "boundary", "id": "antidote-claim-has-limits-q02" } ] } ] } ] }, { "id": "formulation-and-handling-decisions", "name": "Formulation and handling decisions", "description": "Connect atropine material to the evidence governing a proposed use or handling action.", "rationale": "Substance identity alone cannot establish route suitability, product interchangeability or storage requirements.", "layers": [ { "id": "product-context", "name": "Product context", "description": "Keep formulation-dependent properties attached to a specific medicinal product.", "findings": [ { "id": "route-belongs-to-product", "name": "Route belongs to product", "description": "Record labelled route, strength, excipients and relevant quality requirements through a product relation rather than treating them as universal atropine properties.", "questions": [ { "text": "Which product label establishes the intended route and strength basis?", "kind": "provenance", "id": "route-belongs-to-product-q01" }, { "text": "What formulation and quality evidence is required before considering this material suitable for the proposed use?", "kind": "action", "id": "route-belongs-to-product-q02" } ] } ] }, { "id": "exposure-and-storage-controls", "name": "Exposure and storage controls", "description": "Resolve handling decisions against the actual atropine form, concentration and preparation.", "findings": [ { "id": "controls-follow-material-context", "name": "Controls follow material context", "description": "Attach handling, storage and disposal requirements to the relevant safety data sheet, specification or product label, including its revision.", "questions": [ { "text": "Which safety document covers this chemical form, concentration and physical presentation?", "kind": "provenance", "id": "controls-follow-material-context-q01" }, { "text": "Do recorded exposure or storage conditions require containment, quarantine or further assessment under that document?", "kind": "action", "id": "controls-follow-material-context-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This describes the chemical substance and its principal medicinal uses, not a specific pharmaceutical product.", "Pharmacopoeial editions, approved indications and regional regulatory status require verification; no sources were consulted.", "Salt form, hydration state and whether quantities refer to salt or free-base equivalents must be checked when comparing product specifications." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Atropine free base", "Atropine sulfate" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "CAS Registry Number", "value_or_pattern": "51-55-8", "note": "Identifies atropine free base; salts have separate identifiers." }, { "scheme": "Molecular formula", "value_or_pattern": "C17H23NO3", "note": "Formula of the free base." }, { "scheme": "ATC", "value_or_pattern": "A03BA01", "note": "WHO classification for atropine in the belladonna alkaloid group." }, { "scheme": "ATC", "value_or_pattern": "S01FA01", "note": "WHO classification for ophthalmic atropine." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "United States Pharmacopeia-National Formulary, published by the United States Pharmacopeial Convention, includes quality specifications for atropine sulfate.", "European Pharmacopoeia, published by the Council of Europe's European Directorate for the Quality of Medicines & HealthCare, includes quality specifications for atropine sulfate." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Treatment of symptomatic bradycardia in appropriate clinical settings.", "Antidotal treatment of muscarinic effects of organophosphate and other cholinesterase inhibitor poisoning.", "Ophthalmic dilation of the pupil and paralysis of accommodation.", "Reduction of salivary and respiratory secretions in selected perioperative settings.", "Low-concentration ophthalmic preparations for slowing childhood myopia progression in some clinical settings." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of atropine free base", "typical_range": "289.37", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Excess exposure can cause an antimuscarinic toxidrome, including dry mouth, dilated pupils, tachycardia, urinary retention, delirium and hyperthermia.", "Reduced sweating can impair heat dissipation.", "Pupillary dilation can precipitate acute angle closure in susceptible eyes.", "Ophthalmic administration can produce systemic toxicity, particularly in children.", "In cholinesterase inhibitor poisoning, atropine does not directly reverse nicotinic neuromuscular weakness." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, available formulations and prescription requirements vary by jurisdiction.", "Regulatory approval and clinical use of low-concentration atropine for myopia control vary by country." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Hyoscyamine", "difference": "Medicinal hyoscyamine is the levorotatory enantiomer; atropine is the racemic mixture." }, { "name": "Scopolamine", "difference": "A distinct tropane antimuscarinic alkaloid with an additional oxygen bridge and a different clinical effect profile." }, { "name": "Atropine sulfate", "difference": "A salt form of atropine, commonly used in medicines, rather than a different active alkaloid." }, { "name": "Pralidoxime", "difference": "An oxime that can reactivate inhibited acetylcholinesterase under suitable conditions; atropine instead blocks muscarinic receptors." }, { "name": "Atropa belladonna", "difference": "A plant containing tropane alkaloids, rather than the isolated chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of atropine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does an existing Vercy world model already cover atropine, requiring this registry entry to link to it?", "Which authoritative chemical identifiers unambiguously distinguish racemic atropine, its individual enantiomers and its salt forms?", "Which analytical methods and acceptance limits adequately establish racemic composition and distinguish relevant tropane alkaloids?", "Which current monographs establish form-specific assay, impurity and stability requirements for the materials this catalogue will encounter?", "How should the registry connect atropine sulfate and individual medicinal products without duplicating the atropine substance model?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 19, "questions": 29 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "device, machine or tool", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a atropine, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an agent to identify atropine, assess evidence about its material state and biological activity, and determine which handling or use decisions require product-specific authority.", "characteristics": { "substance": "material", "origin": "manufactured", "agency": "inert", "mobility": "varies" }, "whatYouCanDoWithIt": [ "observed and measured" ], "distinguishingFeatures": [ "Described in 69 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a atropine, and on what evidence are they told apart?" ], "whatItIsMadeOf": "matter you can touch", "physicalCharacter": [ "Mobility varies between examples.", "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state" ], "howItIsRecognised": [ "Recognised by form, by the arrangement of its controls, and by markings - a plate, a model number, a certification mark. Form alone rarely separates two models that do very different things." ], "relatedModels": [], "standing": "Described in 69 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one atropine from another, and a atropine from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a atropine sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a atropine from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "form-and-composition", "name": "Form, composition and condition", "description": "What a atropine is made of, what shape and size it takes, and what state it is in.", "rationale": "A physical thing can be measured, and a model that cannot record its measurements cannot support any decision that depends on them.", "layers": [ { "id": "form-and-dimensions", "name": "Form and dimensions", "description": "Shape, size, mass and the ranges these take across examples.", "findings": [ { "id": "measurable-dimensions", "name": "Measurable dimensions and their units", "description": "The quantities worth recording and the units they are recorded in.", "questions": [ { "id": "measurable-dimensions-q01", "text": "What identifies and describes the dimensions of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "measurable-dimensions-q02", "text": "Who or what asserted this about the dimensions of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "measurable-dimensions-q03", "text": "What may an agent decide or do once the dimensions of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "material-and-composition", "name": "Material and composition", "description": "Materials, parts and how they are put together.", "findings": [ { "id": "parts-and-materials", "name": "Parts and materials", "description": "What a atropine is built from and which parts are replaceable.", "questions": [ { "id": "parts-and-materials-q01", "text": "What identifies and describes the composition of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "parts-and-materials-q02", "text": "Who or what asserted this about the composition of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "parts-and-materials-q03", "text": "What may an agent decide or do once the composition of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "condition-and-integrity", "name": "Condition and integrity", "description": "Wear, damage, health and the difference between working and broken.", "findings": [ { "id": "condition-assessment", "name": "Condition, damage and health", "description": "How the condition of a atropine is judged and by whom.", "questions": [ { "id": "condition-assessment-q01", "text": "What identifies and describes the condition of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "condition-assessment-q02", "text": "Who or what asserted this about the condition of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "condition-assessment-q03", "text": "What may an agent decide or do once the condition of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "place-and-movement", "name": "Place and movement", "description": "Where a atropine is, how it got there and where it may go (varies).", "rationale": "A thing that can move needs its position recorded with a time, or every later claim about it is about a place it has left.", "layers": [ { "id": "location-and-placement", "name": "Location and placement", "description": "Position, containment and the reference frame the position is given in.", "findings": [ { "id": "position-and-frame", "name": "Position, container and reference frame", "description": "Where a atropine is, and what that position is measured against.", "questions": [ { "id": "position-and-frame-q01", "text": "What identifies and describes the location of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "position-and-frame-q02", "text": "Who or what asserted this about the location of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "position-and-frame-q03", "text": "What may an agent decide or do once the location of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "movement-and-transfer", "name": "Movement and transfer", "description": "How a atropine is carried, installed or relocated.", "findings": [ { "id": "movement-events", "name": "Movement events and constraints", "description": "What counts as a movement, what records it and what limits it.", "questions": [ { "id": "movement-events-q01", "text": "What identifies and describes the movement of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "movement-events-q02", "text": "Who or what asserted this about the movement of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "movement-events-q03", "text": "What may an agent decide or do once the movement of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a atropine passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a atropine between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a atropine, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a atropine is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "function-and-principle", "name": "Function and operating principle", "description": "What atropine is for and how it achieves it.", "rationale": "Two devices with the same name can work on different principles, and the principle is what predicts failure and constrains use.", "layers": [ { "id": "intended-function", "name": "Intended function", "description": "The job it does, and the jobs it is used for anyway.", "findings": [ { "id": "function-record", "name": "Function, principle and variants", "description": "What it does, how, and which variants do it differently.", "questions": [ { "id": "function-record-q01", "text": "What function does atropine perform, on what operating principle, and which variants differ in that principle?", "kind": "definition" }, { "id": "function-record-q02", "text": "What use falls outside the intended function but happens in practice?", "kind": "boundary" } ] } ] }, { "id": "capacity-and-rating", "name": "Capacity and rating", "description": "The numbers that say what it can do and where it stops.", "findings": [ { "id": "ratings", "name": "Ratings and their conditions", "description": "Rated capacity, power, throughput and the conditions each assumes.", "questions": [ { "id": "ratings-q01", "text": "What ratings characterise atropine, in what units, and under what stated conditions?", "kind": "measurement" }, { "id": "ratings-q02", "text": "What happens beyond the rating - degradation, refusal, damage - and how is that detected?", "kind": "action" } ] } ] } ] }, { "id": "operation-and-state", "name": "Operation, controls and state", "description": "How atropine is operated and what state it is in right now.", "rationale": "An agent acting on a device needs its current state and the controls that change it, not just its specification.", "layers": [ { "id": "controls-and-modes", "name": "Controls and modes", "description": "What can be set, what that changes, and what is interlocked.", "findings": [ { "id": "control-surface", "name": "Control surface and interlocks", "description": "The settings available and the conditions that block them.", "questions": [ { "id": "control-surface-q01", "text": "What controls and modes does atropine have, and what does each change?", "kind": "definition" }, { "id": "control-surface-q02", "text": "Which actions are interlocked or forbidden in which state, and what must be true before acting?", "kind": "action" } ] } ] }, { "id": "condition-and-maintenance", "name": "Condition and maintenance", "description": "Wear, service intervals, consumables and the line between working and broken.", "findings": [ { "id": "service-record", "name": "Condition, service and consumables", "description": "What is consumed, what is serviced, and how condition is judged.", "questions": [ { "id": "service-record-q01", "text": "What consumables and service does atropine need, at what interval, and on whose authority?", "kind": "measurement" }, { "id": "service-record-q02", "text": "What evidence separates a unit that is working from one that is out of service?", "kind": "boundary" } ] } ] } ] }, { "id": "kind-model-unit", "name": "Kind, model and unit", "description": "Whether a claim about atropine is about the kind, a product line, or one physical unit.", "rationale": "This is the boundary most often got wrong for made things, and getting it wrong mixes a catalogue entry with the machine in the yard.", "layers": [ { "id": "level-of-reference", "name": "Level of reference", "description": "The three levels and what belongs at each.", "findings": [ { "id": "level-rules", "name": "What belongs to kind, model and unit", "description": "Which properties are shared by all of them and which are not.", "questions": [ { "id": "level-rules-q01", "text": "Which facts about atropine hold for every one of them, which for a model, and which only for one unit?", "kind": "boundary" }, { "id": "level-rules-q02", "text": "What identifies an individual unit, and what should an agent do when it has only the kind?", "kind": "action" } ] } ] }, { "id": "standards-and-conformity", "name": "Standards and conformity", "description": "The standards a working example must meet and who attests it.", "findings": [ { "id": "conformity", "name": "Standards, marks and attestation", "description": "Which standard applies, who certifies, and what the mark means.", "questions": [ { "id": "conformity-q01", "text": "Which standards govern atropine, issued by whom, and what does conformity actually assert?", "kind": "provenance" }, { "id": "conformity-q02", "text": "What may an agent conclude from a certification mark, and what may it not?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a atropine came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a atropine and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a atropine is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a atropine, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a atropine, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a atropine is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 8, "layers": 17, "findings": 19, "questions": 51 } } } }